Does Screening Save Lives?
Data from a large-scale trial suggest that screening cuts ovarian cancer mortality rates by 25 percent – but some remain skeptical
Ian Jacobs |
The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is one of the largest clinical trials ever conducted worldwide – 202,000 women in 13 regions across the UK are involved. The study estimates a 15–28 percent reduction in mortality attributable to ovarian cancer screening via annual blood tests for CA125 (1), but many have reacted with caution at this stage. We spoke with lead author Ian Jacobs, professor at University College London’s Department of Women's Cancer, to find out more.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.